ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AVRX Avalon Pharmaceuticals (MM)

0.59
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Avalon Pharmaceuticals (MM) NASDAQ:AVRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.59 0 01:00:00

Avalon to Release First Quarter 2007 Financial Results

02/05/2007 1:00pm

PR Newswire (US)


Avalon (NASDAQ:AVRX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Avalon Charts.
GERMANTOWN, Md., May 2 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX) today announced that it is scheduled to release financial results for the first quarter of 2007, on Wednesday, May 9, 2007 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, May 10, 2007 at 8:00 a.m. Eastern Daylight Savings Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the Company's website or by dialing the numbers listed below. Conference Call Details: ------------------------ Dial-In: 866.202.3109 (U.S.) 617.213.8844 (International) Passcode: 34650950 Webcast: Please go to: http://www.avalonrx.com/, Investor Relations/ Upcoming Presentations, within 15 minutes prior to the call and select the webcast link. The conference call replay will be available through June 30, 2007 About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company using its proprietary technology, AvalonRx(R), to discover and develop cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944 - IMPDH inhibitor), as well as preclinical programs to discover inhibitors for the beta-catenin and aurora pathways now in late stage lead candidate optimization. Avalon also has discovery programs on modulators of survivin function and a drug discovery program targeting the MYC oncoprotein, one of the most important and previously intractable cancer targets. The company has value generating partnerships with Merck, MedImmune, Medarex, and Novartis. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Md. DATASOURCE: Avalon Pharmaceuticals CONTACT: David Muth, Executive Vice President and Chief Business Officer of Avalon Pharmaceuticals, +1-301-556-9900, Web site: http://www.avalonrx.com/

Copyright

1 Year Avalon Chart

1 Year Avalon Chart

1 Month Avalon Chart

1 Month Avalon Chart

Your Recent History

Delayed Upgrade Clock